S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:AUPH

Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

$5.13
+0.18 (+3.64%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.90
$5.19
50-Day Range
$4.64
$8.14
52-Week Range
$4.49
$24.45
Volume
2.45 million shs
Average Volume
2.74 million shs
Market Capitalization
$729.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
138.8% Upside
$12.25 Price Target
Short Interest
Healthy
5.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.84) to ($0.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

697th out of 1,043 stocks

Pharmaceutical Preparations Industry

338th out of 510 stocks

AUPH stock logo

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 7.1% Higher
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
Why Aurinia Pharmaceuticals Stock Is Plunging
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings
11/02/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.25
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+138.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-180,970,000.00
Pretax Margin
-88.18%

Debt

Sales & Book Value

Annual Sales
$45.60 million
Book Value
$2.98 per share

Miscellaneous

Free Float
136,852,000
Market Cap
$729.02 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Peter S. Greenleaf M.B.A.Mr. Peter S. Greenleaf M.B.A. (Age 52)
    Pres, CEO & Director
    Comp: $1.24M
  • Mr. Joseph M. Miller CPAMr. Joseph M. Miller CPA (Age 48)
    Chief Financial Officer
    Comp: $710.03k
  • Mr. Matthew Maxwell Donley M.B.A.Mr. Matthew Maxwell Donley M.B.A. (Age 53)
    Exec. VP of Operations & Strategy
    Comp: $730.21k
  • Mr. Stephen P. Robertson (Age 40)
    Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $722.4k
  • Ms. DeDe Sheel
    VP of Investor Relation
  • Mr. Chris Hays
    VP of Marketing
  • Mr. Fran Lynch
    VP of Sales
  • Dr. Robert B. Huizinga M.Sc. (Age 57)
    Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Research
  • Mr. Michael R. Martin (Age 50)
    Chief Bus. Officer
  • Dr. Neil SolomonsDr. Neil Solomons (Age 54)
    Chief Medical Officer













AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $10.00 to $14.00. On average, they predict the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 138.8% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2022?

Aurinia Pharmaceuticals' stock was trading at $22.87 at the beginning of 2022. Since then, AUPH stock has decreased by 77.6% and is now trading at $5.13.
View the best growth stocks for 2022 here
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 8,290,000 shares, a decrease of 27.7% from the October 31st total of 11,460,000 shares. Based on an average trading volume of 2,530,000 shares, the short-interest ratio is presently 3.3 days.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.06. The biotechnology company had revenue of $14.67 million for the quarter, compared to analysts' expectations of $14.70 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 26.03% and a negative net margin of 89.50%. During the same period last year, the firm earned ($0.28) earnings per share.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.43%), Bellevue Group AG (2.00%), State Street Corp (1.72%), Vanguard Group Inc. (0.85%), Renaissance Technologies LLC (0.52%) and Armistice Capital LLC (0.51%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $5.13.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $729.02 million and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

The company employs 300 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 12/1/2022 by MarketBeat.com Staff